Tang Hua-Yu, Yu Tao, Wei Wei, Zhao Yu
Second Ward of Orthopedics Department, First Affiliated Hospital of Jiamusi University, Jiamusi.
Department of Orthopedics, Huludao Central Hospital, Huludao, China.
Medicine (Baltimore). 2019 Feb;98(7):e14517. doi: 10.1097/MD.0000000000014517.
Previous clinical studies have reported that extracorporeal shock wave (EPSW) is an effective treatment for patients with tennis elbow (TE). However, no systematic review has assessed its effectiveness and safety for the treatment of TE.
In this systematic review, we will search the potential eligible literature from the following electronic databases: Central, Embase, MEDLINE, CINAHL, and CNKI from inception to the present. All literatures of randomized controlled trials of EPSW for TE will be considered without language restrictions. Two reviewers will independently select the studies, extract the data, and evaluate the methodology quality. All disagreements between those 2 reviewers will be resolved by a third reviewer involved through discussion. Outcome data will be pooled by RevMan 5.3 software if the heterogeneity is reasonable. Reporting bias will also be conducted if more than 10 included studies can be reached.
This systematic review will evaluate the clinical effectiveness and safety of EPSW for TE.
The findings of this study will summarize the current evidence of EPSW on TE outcomes and may provide guidance for both clinical practice and further studies.
This systematic review does not need ethical approval, because it does not utilize the individual patient data. Its findings are expected to publish in peer-reviewed journals.
PROSPERO CRD42019119687.
既往临床研究报道，体外冲击波（EPSW）是治疗网球肘（TE）患者的一种有效方法。然而，尚无系统评价评估其治疗TE的有效性和安全性。
在本系统评价中，我们将检索以下电子数据库从建库至目前的潜在合格文献：Cochrane中心对照试验注册库、Embase、医学索引数据库、护理学与健康领域数据库以及中国知网。将纳入所有关于EPSW治疗TE的随机对照试验文献，无语言限制。两名评价者将独立选择研究、提取数据并评估方法学质量。这两名评价者之间的所有分歧将通过第三名评价者参与讨论来解决。如果异质性合理，结局数据将采用RevMan 5.3软件进行合并。如果纳入研究超过10项，还将进行发表偏倚分析。
本系统评价将评估EPSW治疗TE 的临床有效性和安全性。
本研究结果将总结目前EPSW对TE结局的证据，并可能为临床实践和进一步研究提供指导。
本系统评价无需伦理批准，因为它不使用个体患者数据。其研究结果有望发表在同行评审期刊上。
国际前瞻性系统评价注册库CRD42019119687。
